Abstract
This study aimed to investigate the effects of colchicine on growth parameters in familial Mediterranean fever (FMF) patients. Fifty-one (29 girls, 22 boys) FMF patients were enrolled in the study. All of the patients were in the prepubertal stage and had not received colchicine treatment before the study. Anthropometric measurements, demographic features, clinical findings at diagnosis and during periods of attacks of FMF, disease activity, frequency of exacerbations, colchicine dosage, and weight and height measurements were recorded at an interval of 6 months. Height, weight, and body mass index standard deviation scores and Z-scores were calculated. The mean height standard deviation score (HSDS) was significantly increased from −0.64 ± 1.20 to −0.26 ± 1.07 (p < 0.001), the mean weight standard deviation score (WSDS) was significantly increased from −0.60 ± 1.03 to −0.45 ± 0.98 (p = 0.008), and the mean body mass index standard deviation score was decreased from −0.33 ± 1.06 to −0.47 ± 0.98 (p = 0.128) at 1 year after colchicine treatment compared with before initiation of treatment. In patients who had no FMF attacks during colchicine treatment, height and weight were significantly increased at 1 year (HSDS: p < 0.001 WSDS: p = 0.002), but in patients who had recurrent attacks, height and weight did not change (HSDS: p = 0.051, WSDS: p = 0.816). Even when subclinical inflammation is present, preventing attacks of FMF with colchicine allows growth to continue. However, suppression of subclinical inflammation and control of attacks of FMF are required for weight gain.
Similar content being viewed by others
References
Gang N, Drenth JP, Langevitz P et al (1999) A. Activation of the cytokine network in familial Mediterranean fever. J Rheumatol 26:890–897
De Benedetti F, Alonzi T, Moretta A et al (1997) Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin like growth factor-1: a model for stunted growth in children with chronic inflammation. J Clin Invest 99:643–650
Bakkaloğlu A (2003) Familial Mediterranean fever. Pediatr Nephrol 18:853–859
Lachmann HJ, Sengul B, Yavuzsen TU, Booth DR, Booth SE (2006) Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations. Rheumatology (Oxford) 45:746–750
Ozçakar B, Kadıoğlu G, Sıklar Z et al (2010) The effect of colchicine on physical growth in children with familial Mediterranean fever. Eur J Pediatr 169(7):825–828
Zung A, Barash G, Zadik Z, Barash J (2006) Familial Mediterranean fever and growth: effect of disease severity and colchicine treatment. J Pediatr Endocrinol Metab 19(2):155–160
Türkmen M, Soylu OB, Kasap B et al (2008) Growth in familial Mediterranean fever: effect of attack rate, genotype and colchicine treatment. J Pediatr Endocrinol Metab 21(8):789–792
Yalçınkaya F, Ozen S, Ozçakar B et al (2009) A new set of criteria for the diagnosis of familial Mediterranean fever in childhood. Rheumatology (Oxford) 48:395–398
Livneh A, Langevitz P, Zemer D et al (1996) The changing of familial Mediterranean fever. Semin Arthritis Rheum 26:612–627
Pras E, Livneh A, Balow JE Jr (1998) Clinical differences between North African and Iraqi Jews with familial Mediterranean fever. Am J Med Genet 75:216–219
Marshall WA, Tanner JM (1969) Variations in pattern of pubertal changes in girls. Arch Dis Child 44:291–303
Marshall WA, Tanner JM (1970) Variations in pattern of pubertal changes in boys. Arch Dis Child 45:13–23
Zemer D, Livneh A, Danon T et al (1991) Long term colchicine treatment in children with familial Mediterranean fever. Arthritis Rheum 34:973–977
Ben-Cherit E, Levy M (1991) Colchicine prophylaxis in familial Mediterranean fever: reappraisal after 15 years. Semin Arthritis Rheum 20:241–246
Savgan-Gürol E, Kasapçopur Ö, Hatemi S et al (2001) Growht and IGF-1 levels of children with familial Mediterranean fever on colchicine treatment. Clin Exp Rheumatol 19(Suppl 24):72–75
Padeh S, Gerstein M, Berkun Y (2012) Colchicine is a safe drug in children with familial Mediterranean fever. J Pediatr 161:1142–1146
Goldfinger SE (1972) Colchicine for familial Mediterranean fever. N Engl J Med 287:1302
Goldfinger S (2009) The inherited autoinflammatory syndrome: a decade of discovery. Trans Am Clin Climatol Assoc 120:413–418
Ozkan E, Okur O, Ekmekci A et al (1972) A new approach to the treatment of periodic fever. Med Bull Istanbul 5:44–49
Zemer D, Revach M, Pras M et al (1974) A controlled trial of colchicine in preventing attacks of familial Mediterranean fever. N Engl J Med 291:932–934
Başaran Ö, Uncu N, Çelikel BA et al (2014) Interleukin-1 targeting treatment in familial Mediterranean fever: an experience of pediatric patients. Mod Rheumatol 22:1–4
Meinzer U, Quartier P, Alexandra JF et al (2011) Interleukin-1 targeting drugs in familial Mediterranean fever: a case series and a review of the literature. Semin Arthritis Rheum 41:265–71
Disclosure
None.
Compliance with ethical standards
ᅟ
Ethics approval
The study was approved by the local hospital ethics committee and performed according to the Declaration of Helsinki and Good Clinical Practice guidelines.
Consent to participate
Written informed consent was obtained from every participant.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yoldaş, T.Ç., Çakar, N., Başaran, Ö. et al. The effect of colchicine and disease severity on physical growth in children with familial Mediterranean fever. Clin Rheumatol 35, 1603–1607 (2016). https://doi.org/10.1007/s10067-015-3077-9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-015-3077-9